Skip to content
About Us
Our Founders & Our Story
Leadership
Advisory Board
Our Team
Our Values
Investors
MicroOrganoSphere
TM
(MOS)
Technology
Precision
Oncology
Colorectal Cancer
Breast Cancer
Immuno-oncology
Drug
Development
Collaborators
News &
Publications
Careers
Contact Us
Menu
A novel and rapid patient-derived organoid breast cancer platform for precision medicine
Post navigation
Previous Post
Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS)
TM
enables correlation of targeted therapy combination response with clinical outcomes
Next Post
Biotech Startups Use Models of Human Organs for Drug Discovery
vera
View posts by vera
Scroll to top
Copy
Email
Share on Mastodon
Enter your Mastodon instance URL (optional)
Share
